TrialLancet (London, England)2013

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

Mathias J Rummel et al.PubMed ↗Publisher ↗

No numbers read from the abstract.